JP2024545441A - 脂肪肝の予防、及び治療 - Google Patents

脂肪肝の予防、及び治療 Download PDF

Info

Publication number
JP2024545441A
JP2024545441A JP2024533245A JP2024533245A JP2024545441A JP 2024545441 A JP2024545441 A JP 2024545441A JP 2024533245 A JP2024533245 A JP 2024533245A JP 2024533245 A JP2024533245 A JP 2024533245A JP 2024545441 A JP2024545441 A JP 2024545441A
Authority
JP
Japan
Prior art keywords
related species
soehngenii
anaerobutyricum
closely related
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545441A5 (enExample
Inventor
アー・ヘー・ホレボーム
マックス・ニウドルプ
ヴィレム・メインデルト・デ・フォス
Original Assignee
カイルス・ファーマシューティカルズ・ベー・フェー
シュティッヒティング・アムステルダム・ウーエムセー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイルス・ファーマシューティカルズ・ベー・フェー, シュティッヒティング・アムステルダム・ウーエムセー filed Critical カイルス・ファーマシューティカルズ・ベー・フェー
Publication of JP2024545441A publication Critical patent/JP2024545441A/ja
Publication of JP2024545441A5 publication Critical patent/JP2024545441A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2024533245A 2021-12-03 2022-11-30 脂肪肝の予防、及び治療 Pending JP2024545441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2030011 2021-12-03
NL2030011A NL2030011B1 (en) 2021-12-03 2021-12-03 Prevention or treatment of hepatic steatosis
PCT/EP2022/083885 WO2023099579A1 (en) 2021-12-03 2022-11-30 Prevention or treatment of hepatic steatosis

Publications (2)

Publication Number Publication Date
JP2024545441A true JP2024545441A (ja) 2024-12-06
JP2024545441A5 JP2024545441A5 (enExample) 2025-12-10

Family

ID=80448857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533245A Pending JP2024545441A (ja) 2021-12-03 2022-11-30 脂肪肝の予防、及び治療

Country Status (7)

Country Link
US (1) US20250025517A1 (enExample)
EP (1) EP4440588A1 (enExample)
JP (1) JP2024545441A (enExample)
CN (1) CN118660712A (enExample)
NL (1) NL2030011B1 (enExample)
TW (1) TW202332457A (enExample)
WO (1) WO2023099579A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025077370A1 (zh) * 2023-10-12 2025-04-17 雷文虎克生物技术股份有限公司 艾克曼嗜黏蛋白菌及其用于预防非酒精性脂肪肝炎的用途
WO2025229145A1 (en) 2024-05-02 2025-11-06 Stichting Amsterdam UMC Desulfovibrio piger species for prevention or treatment of hepatic steatosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140096A1 (en) * 2019-05-21 2020-11-26 Pendulum Therapeutics, Inc. Methods and compositions for treating liver disorders
WO2021204719A1 (en) 2020-04-07 2021-10-14 Wholefiber Holding B.V. Particles comprising inulin for use as medicament or supplement

Also Published As

Publication number Publication date
NL2030011B1 (en) 2023-06-20
US20250025517A1 (en) 2025-01-23
WO2023099579A1 (en) 2023-06-08
EP4440588A1 (en) 2024-10-09
CN118660712A (zh) 2024-09-17
TW202332457A (zh) 2023-08-16

Similar Documents

Publication Publication Date Title
Zhang et al. Akkermansia muciniphila is a promising probiotic
Marasco et al. Gut microbiota and celiac disease
JP2022000040A (ja) 代謝障害を処置するための低温殺菌アッカーマンシアの使用
Gopal et al. Effects of the consumption of Bifidobacterium lactis HN019 (DR10TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects
CN111603488B (zh) 阿克曼氏菌属用于治疗代谢病症的用途
Ekhlasi et al. Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial
JP6843140B2 (ja) 肥満および関連する代謝障害を処置するためのビフィドバクテリウム・ロングム
CN102711778B (zh) 利用动物双歧杆菌细菌或含有这种细菌的发酵乳制品减轻胃肠炎症的方法
IL263933A (en) Preparations containing bacterial strains
MX2013006460A (es) Bifidobacterium cect 7765 y su uso en la prevencion y/o tratamiento del sobrepeso, la obesidad y patologias asociadas.
JP2022547330A (ja) 自閉症スペクトラム障害を治療するための組成物および方法
EP2209527B1 (en) Pharmaceutical compositions comprising L. acidophilus and Bifidobacterium lactis for use in the treatment of functional bowel disorder
JP2024545441A (ja) 脂肪肝の予防、及び治療
JP2012180288A (ja) 抗菌剤
Liu et al. A protective mechanism of heat inactivation to enhance Levilactobacillus brevis PDD-2 against alcohol-induced chronic liver disease based on proteomic analysis
EP3889250A1 (en) Phascolarctobacterium faecium for use in the prevention and treatment of obesity and its comorbidities
El-Dalatony et al. Introduction to probiotics and their potential health benefits
Peng et al. Probiotics and prebiotics on intestinal flora and gut health
Leo et al. Probiotics beverages: An alternative treatment for metabolic syndrome
Ajay et al. Probiotics: Immune Responses and Gut Microbiome
WO2021142358A1 (en) Compositions and methods for treating hepatic encephalopathy (he)
Muntingh Ok, so who wants to colonise my gut?-Overview of Probiotics in certain Gastro-intestinal Disorders
WO2025229145A1 (en) Desulfovibrio piger species for prevention or treatment of hepatic steatosis
Wu et al. GOS‐Modulated Gut Microbiota in Mice Ameliorates Obesity in High‐Fat Diet‐Fed Mice Through the Gut‐Liver Axis and Bile Acid Pathway
Azarang et al. Research Article Protective Role of Probiotic Supplements in Hepatic Steatosis: A Rat Model Study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251201

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260413